Hypoglycemic Drug

Phase 2Small molecule

CCairo University

Hypoglycemic Drug is one of 43 small molecule programs targeting Insulin resistance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceRecruiting

Insulin ResistancePhase 2

Recruiting

Competition

Competitive Landscape

65 competitors in Insulin Resistance

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

15 2

Avandia

Jazz Pharmaceuticals

Approved

6 3

Glucophage

EMD Serono

Approved

17 4

Crestor

AstraZeneca

Approved

1 5

Rozerem

Takeda

Approved

1 6

Sovaldi

Gilead

Approved

1 7

Victoza

Novo Nordisk

Approved

1 8

Calciferol

Jazz Pharmaceuticals

Approved

—9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Starlix

Novartis

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Insulin resistance1 trial

Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause

Recruiting·—·Phase 1/2·NCT06806345·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hypoglycemic Drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hypoglycemic Drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hypoglycemic Drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cairo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCairo University

Hypoglycemic Drug

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Insulin resistance1 trial

References

Drug Info

Quick Facts

Related News